Razoxane, (R)-
Basic information
- CAS
24613-06-7- Standard SMILES
C[C@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1- InChIKey
BMKDZUISNHGIBY-SSDOTTSWSA-N- Molecular formula
- C11H16N4O4
- Average molar mass
- 268.27 g/mol
- Monoisotopic mass
- 268.117155
Names & identifiers
- Preferred name
- Razoxane, (R)-
- IUPAC
- 4-[(2R)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
- English name
- ICRF-186
- Molecular formula
- C11H16N4O4
- Molecular weight
- 268.27
Names & synonyms
24613-06-7Razoxane, (R)-LevrazoxaneICRF-186GGX7PSE8Z2NSC-169779(R)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (R)-(R)-(-)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane2,6-Piperazinedione, 4,4'-((1R)-1-methyl-1,2-ethanediyl)bis-RefChem:509088(R)-Levrazoxane
Show more names
NSC 169779(R)-RazoxaneR- DexrazoxaneDexrazoxane Impurity 8Carvedilol Impurity 36(R)-Razoxane (Levrazoxane)
Dexrazoxane Impurity 9(R)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)UNII-GGX7PSE8Z2NSC1697794-[(2R)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione(S)-4,4'-(1-METHYL-1,2-ETHANEDIYL)BIS-2,6-PIPERAZINEDIONENCIMech_000085NCIMech_000121
Database identifiers
- CAS
24613-06-7- PubChem CID
- 298076
- DTXSID
DTXSID50305214- ChEMBL
CHEMBL1231714- UNII
- GGX7PSE8Z2
- EC Number
- 881-618-5
- Nikkaji
- J441.622H
Properties
Computed structural properties
- XLogP
- -1.4
- Topological polar surface area
- 98.8 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 6
- Rotatable bonds
- 3
- Heavy atoms
- 19
- Formal charge
- 0
- Complexity
- 404
Physicochemical properties
- Boiling point
- 531.5 · 531.5±50.0 °C(Predicted)
- Density
- 1.333 · 1.333±0.06 g/cm3(Predicted)
- pka
- 11 · 11.00±0.20(Predicted)
- InChI
- InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1
- InChIKey
- BMKDZUISNHGIBY-SSDOTTSWSA-N
- SMILES
- [C@@H](N1CC(=O)NC(=O)C1)(C)CN1CC(=O)NC(=O)C1
- FDA UNII
- 7 PSE8Z2 · GGX7PSE8Z2
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 315 · H315-H319-H302+H312+H332
- Precautionary statements
- 264 · P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302+H312+H332 (100%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Hazard information
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H315-H319-H302+H312+H332
- Precautionary statements
- P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P
Chemistry & industry
Pharmacology
MeSH Pharmacological ClassificationAgents that arrest cells in MITOSIS, most notably TUBULIN MODULATORS.
Applications
Uses(R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases[1].
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…